Is CERo Therapeutics Stock a Good Investment?
CERo Therapeutics Investment Advice | CEROW |
- Examine CERo Therapeutics' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research CERo Therapeutics' leadership team and their track record. Good management can help CERo Therapeutics navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Pharmaceutical Products space and any emerging trends that could impact CERo Therapeutics' business and its evolving consumer preferences.
- Compare CERo Therapeutics' performance and market position to its competitors. Analyze how CERo Therapeutics is positioned in terms of product offerings, innovation, and market share.
- Check if CERo Therapeutics pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about CERo Therapeutics' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in CERo Therapeutics Holdings stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if CERo Therapeutics Holdings is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Good | Details | |
Volatility | Out of control | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Quite High | Details | |
Economic Sensitivity | Moves completely opposite to the market | Details | |
Investor Sentiment | Interested | Details | |
Analyst Consensus | Not Available | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Inapplicable | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine CERo Therapeutics Stock
Researching CERo Therapeutics' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). The company had not issued any dividends in recent years.
To determine if CERo Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding CERo Therapeutics' research are outlined below:
| CERo Therapeutics is way too risky over 90 days horizon | |
| CERo Therapeutics has some characteristics of a very speculative penny stock | |
| CERo Therapeutics appears to be risky and price may revert if volatility continues | |
| CERo Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| CERo Therapeutics Holdings was previously known as Phoenix Biotech Acquisition and was traded on NASDAQ Exchange under the symbol PBAXW. | |
| Net Loss for the year was (2.54 K) with profit before overhead, payroll, taxes, and interest of 0. | |
| CERo Therapeutics generates negative cash flow from operations | |
| CERo Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Latest headline from news.google.com: Cero Therapeutics holdings sees 400,456 in stock sales by YK Bioventures - Investing.com |
CERo Therapeutics' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Capital Employed | (0.87) | (0.82) |
Determining CERo Therapeutics' profitability involves analyzing its financial statements and using various financial metrics to determine if CERo Therapeutics is a good buy. For example, gross profit margin measures CERo Therapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of CERo Therapeutics' profitability and make more informed investment decisions.
Please note, the imprecision that can be found in CERo Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of CERo Therapeutics Holdings. Check CERo Therapeutics' Beneish M Score to see the likelihood of CERo Therapeutics' management manipulating its earnings.
Evaluate CERo Therapeutics' management efficiency
The company has return on total asset (ROA) of (0.4528) % which means that it has lost $0.4528 on every $100 spent on assets. This is way below average. CERo Therapeutics' management efficiency ratios could be used to measure how well CERo Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Equity is likely to climb to 0.0002 in 2024, whereas Return On Tangible Assets are likely to drop (0.0003) in 2024. At this time, CERo Therapeutics' Other Current Assets are fairly stable compared to the past year. Debt To Assets is likely to climb to 0.19 in 2024, whereas Total Assets are likely to drop slightly above 8.1 M in 2024.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | (2.18) | (2.07) | |
| Tangible Book Value Per Share | (2.18) | (2.07) | |
| Enterprise Value Over EBITDA | (30.01) | (31.51) | |
| Price Book Value Ratio | (5.06) | (4.80) | |
| Enterprise Value Multiple | (30.01) | (31.51) | |
| Price Fair Value | (5.06) | (4.80) | |
| Enterprise Value | 32.2 M | 30.6 M |
The management team at CERo Therapeutics has a track record of steering the company towards sustained growth. Evaluating their strategies helps in understanding the stock's long-term potential.
Beta (0.46) |
Basic technical analysis of CERo Stock
As of the 30th of December, CERo Therapeutics shows the mean deviation of 26.02, and Risk Adjusted Performance of 0.1358. CERo Therapeutics technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Please confirm CERo Therapeutics standard deviation, value at risk, as well as the relationship between the Value At Risk and kurtosis to decide if CERo Therapeutics is priced favorably, providing market reflects its regular price of 0.0089999996 per share. As CERo Therapeutics appears to be a penny stock we also recommend to validate its total risk alpha numbers.Understand CERo Therapeutics' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing CERo Therapeutics' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.1358 | |||
| Market Risk Adjusted Performance | (2.08) | |||
| Mean Deviation | 26.02 | |||
| Semi Deviation | 22.43 | |||
| Downside Deviation | 25.82 | |||
| Coefficient Of Variation | 632.55 | |||
| Standard Deviation | 35.7 | |||
| Variance | 1274.42 | |||
| Information Ratio | 0.1572 | |||
| Jensen Alpha | 5.69 | |||
| Total Risk Alpha | 4.64 | |||
| Sortino Ratio | 0.2174 | |||
| Treynor Ratio | (2.09) | |||
| Maximum Drawdown | 191.74 | |||
| Value At Risk | (40.00) | |||
| Potential Upside | 66.67 | |||
| Downside Variance | 666.54 | |||
| Semi Variance | 503.05 | |||
| Expected Short fall | (34.98) | |||
| Skewness | 1.38 | |||
| Kurtosis | 3.12 |
| Risk Adjusted Performance | 0.1358 | |||
| Market Risk Adjusted Performance | (2.08) | |||
| Mean Deviation | 26.02 | |||
| Semi Deviation | 22.43 | |||
| Downside Deviation | 25.82 | |||
| Coefficient Of Variation | 632.55 | |||
| Standard Deviation | 35.7 | |||
| Variance | 1274.42 | |||
| Information Ratio | 0.1572 | |||
| Jensen Alpha | 5.69 | |||
| Total Risk Alpha | 4.64 | |||
| Sortino Ratio | 0.2174 | |||
| Treynor Ratio | (2.09) | |||
| Maximum Drawdown | 191.74 | |||
| Value At Risk | (40.00) | |||
| Potential Upside | 66.67 | |||
| Downside Variance | 666.54 | |||
| Semi Variance | 503.05 | |||
| Expected Short fall | (34.98) | |||
| Skewness | 1.38 | |||
| Kurtosis | 3.12 |
Consider CERo Therapeutics' intraday indicators
CERo Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of CERo Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Accumulation Distribution | 0.16 | |||
| Rate Of Daily Change | 1.0 | |||
| Day Median Price | 0.0083 | |||
| Day Typical Price | 0.0085 | |||
| Market Facilitation Index | 0.0014 | |||
| Price Action Indicator | 7.0E-4 |
CERo Stock media impact
Far too much social signal, news, headlines, and media speculation about CERo Therapeutics that are available to investors today. That information is available publicly through CERo media outlets and privately through word of mouth or via CERo internal channels. However, regardless of the origin, that massive amount of CERo data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of CERo Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of CERo Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to CERo Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive CERo Therapeutics alpha.
CERo Therapeutics Corporate Executives
Elected by the shareholders, the CERo Therapeutics' board of directors comprises two types of representatives: CERo Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of CERo. The board's role is to monitor CERo Therapeutics' management team and ensure that shareholders' interests are well served. CERo Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, CERo Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Lawrence MD | Cofounder Board | Profile | |
| Charles Carter | Treasurer, CFO | Profile |
Additional Tools for CERo Stock Analysis
When running CERo Therapeutics' price analysis, check to measure CERo Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CERo Therapeutics is operating at the current time. Most of CERo Therapeutics' value examination focuses on studying past and present price action to predict the probability of CERo Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move CERo Therapeutics' price. Additionally, you may evaluate how the addition of CERo Therapeutics to your portfolios can decrease your overall portfolio volatility.